We’ve analysed 10 years’ worth of clinical trials data from GlobalData to pick out key geographic trends.
The Asia-Pacific region has seen a 38% increase in the number of cardiovascular trials taking place over the past decade, the largest increase for any region worldwide.
The region now ranks first for the total number of trials taking place, compared to its third placed ranking in 2010.
These figures come from GlobalData’s extensive clinical trials database which seeks to track the number of clinical trials taking place in countries around the world, in numerous therapy areas.
Asia-Pacific
The Asia-Pacific region saw the biggest increase in cardiovascular related trials.
In 2020, the largest proportion of trials in the region took place in China with 60.6% of all trials in the region taking place there.
South Korea and India had the next largest percentage of trials taking place in the region with 8.4% and 7.6%, respectively.
Middle East
The Middle East saw a 33% increase in the number of cardiovascular trials taking place.
Iran saw the largest amount of trials taking place, in 2020, at 81.1%.
Trials in Israel and Saudi Arabia also made up a large proportion of the trials taking place with 14.4% and 3.8%, respectively.
Africa
Africa saw a 14% increase in the number trials taking place.
Egypt, South Africa and Tunisia made up the most trials in the region, with 81.8%, 6.1% and 3%, respectively.
Europe
Europe saw a 15% decrease in cardiovascular related trials taking place.
Russia saw the largest percentage of trials taking place in the region at 11.2%.
France and the United Kingdom also made up a significant proportion of the trials taking place.
North America
North America saw a decrease in the number of cardiovascular trials.
The region saw a 16% decrease in the number of trials.
The United States made up 72.8% the largest proportion of trials taking place in the region.
Canada and Mexico also made up a large amount of the trials taking place with 21.5% and 5.7%, respectively.
South and Central America
South and Central America saw the biggest decrease in cardiovascular trials.
The number of trials in the region fell by 42% between 2010 and 2020.
Brazil saw the largest percentage of trials taking place in the region with 57.1%.
